No products in the cart.
Pre-made Ieramilimab benchmark antibody ( Whole mAb, anti-CD223/LAG3 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-262
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ieramilimab biosimilar, Whole Mab: Anti-CD223/LAG3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that ‘dosing is imminent’ for the first clinical trials of LAG525.
| Products Name (INN Index) | Pre-Made Ieramilimab biosimilar, Whole Mab: Anti-CD223/LAG3 therapeutic antibody |
|---|---|
| INN Name | Ieramilimab |
| Target | LAG3 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Immutep Limited,Novartis |
| Conditions Approved | NA |
| Conditions Active | Breast cancer,Diffuse large B cell lymphoma,Malignant melanoma,Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD223 |
| Package |
Previous slide
Next slide
